Karen A. Gelmon

Group Website


Vision Statement


Karen A. Gelmon




Medical Oncology




Research Interests

Research Summary

Research Highlights


Education and Affiliations


BA (Hons), University of Saskatchewan, Philosophy,

MD, University of Saskatchewan,

FRCPC, University of British Columbia,


Publications and Awards

Recent Publications

  • •Cheang Maggie CU, Treaba Diana O, Speers Caroline H, Olivotto Ivo A, Bajdik Chris D, Chia Stephen K, Goldstein Lynn C, Gelmon Karen A, Huntsman David, Gilks C Blake, Nielsen Torsten O, Gown Allen M.  Immunohistochemical detection of estrogen receptor in breast cancer using the new rabbit monoclonal antibody SPI predicts survival better than mouse monoclonal antibody ID5.  Jour Clin Oncol 2006: 5637-5644.
  • •Chia Stephen, Clemons Mark, Martin Lee Ann, Rodgers Angela, Gelmon Karen, Pond Gregory R, Panasci Lawrence Pegylated liposomal doxorubicin and trastuzumab inHER2 overexpressing metastatic breast cancer. a multicentre phase II Trial.  J Clin Oncol 2006; 24: 2773 – 2778.
  • •Gelmon KA, Chan A, Harbeck N.  Capecitabine in Metastatic Breast Cancer. A Review. The Oncologist, 2006; 11(suppl_1): 42-51.
  • •Kennecke HF, Ellard S, O’Reilly S, Gelmon KA. New guidelines for treatment of early hormone positive breast cancer with tamoxifenand aromatase inhibitors.  BCMJ 2006; 48: 121 – 126.
  • •Lohrisch Caroline, Paltiel Charles, Gelmon Karen, Speers Caroline, Taylor Suzanne, Barnett Jeff, and. Olivotto Ivo A.  Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer. Jour Clin Oncol, 2006; 24:4888-4894.
  • •Robinson, Andrew, Thomson T, Ellard S, Bajdik C, Yorida E, Turbin D, Huntsman D , Gelmon Karen.  Molecular Prognostic and Predictive Factors in patients undergoing trastuzumab based chemotherapy for metastatic breast cancer. Clinical Breast Cancer 2006; 7(3): 254-261.
  • •Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S.  Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin Linked Kinase for PKB-Akt Activation and Cell Survival.  Cancer Research 2006;  66(1): 393-403.
  • •Turbin, DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. MDM2 protein Expression is a negative prognostic marker in breast cancer.  Modern Pathology 2006; 19(1): 69-74.
  • •Waterhouse, DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Zhang YZ, Yapp D, Dargowksa W, Dunn S, Dedhar S, Bally MB.  Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.  Current Cancer Drug Targets 2006; 6: 455- 489.
  • •Campbell KL, Lane K, Martin AD, Gelmon KA, McKenzie DC.  Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer.   Cancer Nurs 2007; 30(2): 95-100.
  • •Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’Reilly SE, Olivotto IA.  The impact of new chemotherapeutic and hormone agents on surivival in a population based cohort of women with metastatic breast cancer. Cancer 2007; 110 (5): 973-9.
  • •Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K, Yasui Y, Segal RJ.  Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial  Accepted Cancer, 2007.
  • •Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K & , MacKenzie DC Effects  of aerobic and  resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial.  Jour Clin Onco. 2007;  25(28): 4306-404.
  • •Courneya KS, Segal, R, Gelmon K, Reid R, Mackey J, Friedenreich CM, Proulx C, Lane K, Ladha AB, , Vallance JK, Lui Q, Yasui Y, McKenzie DC.   Six month follow-up of patient rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy.  Cancer Epidemiology, Biomarkers and Prevention, 2007; 16: 2572-2578.
  • •Dagowksa, WH, Verreault M, Yapp DTT, Warburton C, Edwards L, Ramsay EC, Huxhuam LA, Minchinton A, Gelmon K, Bally M.  Decreased levels of hypoxic cells in gefitinib treated ER+ Her-2 overexpressing MCF-7 breast cancer tumours are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.  Breast Cancer Res Treat 2007;(epub ahead of print).
  • •Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G.  Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a predictive model.  Am Jour Clin Oncol 2008; 31 (4): 369 – 74.
  • •Gelmon K. Prescribing extended adjuvant letrozole.  Breast 2007; 16(5): 446-55.
  • •Ian Smith, Marion Procter, Richard D Gelber, Sebastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Pter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sanchez Rovira, Martine J Piccart-Gebhart for the HERA Study Team. 2 year follow-up of trastuzumab after adjuvant therapy with chemotherapy in HE
  • •Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA.  Late risk of relapse and mortality among postemenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.  Ann Oncol 2007; 8 (1): 45-51.
  • •Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL.  Quantitative justification of the change from 10% – 30 % for HER2 scoring in the ASCO-CAP guidelines: tumour heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. Accepted Jour Clin Oncol, 2007; 25 (34): 5418-25.
  • •Munster Pamela, Britten Carolyn D, Mita Monica, Gelmon Karen,  Minton Susan E, Moulde Stacey, Slamon Dennis, Guo Feng, Letrent Stephen P, Denis Louis, Tolcher Anthony W.  First-in-Human Study of the Safety and Tolerability and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid Tumors that Express HER2, Clinical Cancer Research, 2007 15; 13(4): 1238-45.
  • •Pansegrau GK, Grant DR, Norris B, Gelmon KA. Trastuzumab associated peripheral vascular toxicity.  J Clin Oncol 2007 10; 25 (11): 1438 – 40.
  • •Borugian MJ, Kan L, Bhcu CCY, Ceballos K, Gelmon KA, Gordon B, Tyldesley S, Olivotto IA. Facilitated ‘Fast Track’ referral reduces time from abnormal screening mammogram to diagnosis.  Can Jour Pub Health 2008; 99 (4): 252-6.
  • •Chia, S, Norris, B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivottor IO, Nielsen TO, Gelmon K. HER-2 overexpression as a prognostic factor in a large tissue microarray series of node negative breast cancers. J Clin Oncol 2008 26 (35); 5697 – 704.
  • •Courneya KS, McKenzie DC, Reid RD, Mackey JR, Gelmon K, Friedenreich CM,Ladha AB, Proulx C, Lane K, Vallance JK, Segal RJ.  Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. Ann Behav Med 2008; 35 (1): 116-22.
  • •Courneya KS, Reid RK, Friedenreich CM, Gelmon K, Proulx C, Vallance JK, McKenzie DC, Segal RJ.  Understanding breast cancer patients’ preferences for two types of exercise training during chemotherapy in an unblended randomized controlled trial.  International Journal of behavioural nutrition and physical activity. In J Behav Nutr Phys Act 2008; 5:52 – epub.
  • •Courneya KS, Segal RJ, Gelmon K, Reid RD, Mackey JR, Friedenreich CM, Proulx C, Lane K, Ladha AB, Vallance JK, McKenzie DC,  Predictors of supervised exercise adherence during breast cancer chemotherapy. Medicine and Science in Sports and Exercise 2008; 40 (6):1180 -1187.
  • •Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon KA.  Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers?  A tissue microarray feasibility study.  Breast Cancer Res 2008; 10(1): R6 (epub ahead of print).
  • •Crabb SJ, Chia S, Gelmon K.  Current questions and uncertainty in the treatment of HER2 positive breast cancer.  accepted Breast Cancer Treatment and Research  2008.
  • •Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008; 107: 443 – 450.
  • •FP O’Malley, T Thomson, JA Julian, C Have, R Cosby, K Gelmon, I Andrulis, T Whelan.  HER2/neu testing in a population based study of patients treated with Herceptin: a comparison of local and central testing laboratories. Arch Pathol Lab Med 2008; 132(1): 61-65.
  • •Gelmon KA, Milestones in personalized medicine – trastuzumab. Lancet Oncology, 2008; 9:698.
  • •Giltnane Jena N, Molinaro A, Moeder C, Robinson A, Turbin D, Gelmon K, Huntsman D, Rimm DL.  Prognostic and predictive significance of HER family quantitative multiplexed assessment of protein expression in breast cancer.  Arch Pathol Lab Med 2008; 132 (10): 1635-47.
  • •Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A.  Pharmacokinetics of a HER2 tyrosine kinase inhibitor, CP-724,714 in patients with advanced malignant HER2 positive solid tumors; correlations with clinical characteristics and safety. Cancer Chemother Pharmacol. 2008; 62(1) 97 – 109.
  • •Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.  Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 2008 10(5): R86, Epub ahead of print.
  • •Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA. Risk of Early Recurrence among postmenopausal women with estrogen receptor positive early breast cancer treated with adjuvant tamoxifen.  Cancer 2008; 112 (7): 1437-1444.
  • •Lemieux J, Goodwin PJ, Pritchard KI, Gelmon KA, Bordeleau LJ, Duchesne T, Camden S, Speers CH.  Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials.  Jour Clin Oncol 2008; 26 (27): 4458 – 65.
  • •Perez EA, Suman VJ,. Davidson NE, Sledge GW,. Kaufman PA,. Hudis CA, Martino S, . Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA,. Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial, Jour Clin Oncol 2008; 26 (8): 1231 – 38.
  • •Poole B, Gelmon K, Kan L, Stilwell M. Breast cancer screening and diagnosis in British Columbia. BCMJ 2008 50 (4) 198 – 205.
  • •Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB , Huntsman DG. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4444 cases. Breast Cancer Res Treat 2008; 107 (2): 249-57.
  • •Saad F,  Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI.  Cancer Treatment induced bone loss in breast and prostate cancer.  J Clin Oncol 2008; 26 (33): 5465-76.
  • •Yerushalmi R, Gelmon K.  Chemotherapy for oestrogen-receptor-negative breast cancer. Lancet 2008; 371 (9606): 4-5..
  • •Yerushalmi R, Kennecke H, Woods R, Olivotto I, Speers C, Gelmon K.  Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence.  Breast Cancer Res Treat. 2008 ; epub ahead of print.
  • •Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SKL, Mayer LD, Swenson CE, Janoff AS, Louie AC. Safety, Pharmacokinetics and Efficacy of CPX-1 (Irinotecan HCL: Floxuridine) Liposome injection in patients with advanced solid tumors. Clinical Cancer Res 2009; 15(2): 692 -700.
  • •Borugian MJ, Kan L, Poole B, Xu CL, St Germain L, Gelmon KA.  The top issues patients mention when family physicians recommend screening mammography.  BCMJ, 2009; 51(10): 436-439.
  • •Chia Stephen, Dent Susan, Ellard Susan, Ellis Peter M, Vandenberg Ted, Gelmon Karen, Powers Jean, Walsh Wendy, Seymour Lesley, Eisenhauer Elizabeth.  Phase II trial of OGX 011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Research 2009; 15 (2); 708 – 713.
  • •Courneya KS, Friedenreich CM, Reid RD, Gelmon K, Mackey JR, Ladha AB, Proulx C, Valllance JK, Segal RJ.   Predictors of follow-up exercise behaviour 6 months after a randomized trial of exercise training during breast cancer chemotherapy.  Breast Cancer Res Treat 2009: 114 (1): 179- 87.
  • •Dragowska WH, Qadir MA, Wong LY, Donohue E, Roberge M, Gelmon K, Gorski SM, Bally MB. Gefitinib induces cytoprotective autophagy in breast cancer cells.  AACR, abst 1835.
  • •Ellard SL, Clemons MJ, Gelmon K, Norris BC, Kennecke HF, Chia SK, Pritchard KI, Eisen A, Vandenberg T, Taylor M, Sauerbrei EE, Mishaeli M, Huntsman D, Walsh WR, Olivo M, McIntosh L, Seymour L.  A randomized Phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer; NCIC CTG- IND 163.  Jour Clin Oncol 2009; 27 (9): 1388-93.
  • •Kalra J, Warburton C, Fang K, Edwards L, Dynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M.  QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK) and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in p-AKT levels, alterned F-Actin architecture and improved treatment outcomes in an orthotopic breast cancer model.  Breast Cancer Res 2009; 11 (3): r25.
  • •Mackey J, Gelmon K, Martin M, McCarthy N, Pinter T, Rupin M, Youssoufin H.  TRIO-012: a multicentre, multinational randomized double blind phase II study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patient with HER2 negative unresectable and locally recurrent or metastatic breast cancer.  Clin Breast Cancer 2009; 9 (4): 258 -61l.
  • •Mackey J, McLeod D, Ragaz J, Gelmon K, Verma S, Prichard K, Laing K, Provencher L, Charbonneau LF.  Adjuvant targeted therapy in early breast cancer.  Cancer 2009; 115 (6): 1154 – 68.
  • •Mackey J, McLeod D, Ragaz J, Gelmon K, Verma S, Prichard K, Laing K, Provencher L, Charbonneau LF.  Cancer 2009; Epub ahead of print.
  • •McArthur HL, Gelmon KA, Olivotto IA, Speers CH, Ellard SL, O’Reilly SE, Kennecke HF.  The effectiveness of a letter notification program for women with early stage breast cancer eligible for extended adjuvant letrozole.  Jour Clin Oncol, 2009; 27 (9): 1388 – 93.
  • •Shah S, Morin R, Khattra J, Prentice L, Pugh TJ, Burleigh A, Delaney A, Gelmon K, Guliany R, Holt R, Jones S Sun M, Moore R, Teschendorff A, Tse K, Turashvili G, Varhol R, Warren R, Watson P, Zhao Y, Caldas C, Hunstman D, Hirst M, Marra M,  paricio S.  Mutational evolution of a lobular breast tumour, profiled by whole transcriptonme and whole genome next generation sequencing.  Nature 2009; 461 (7265): 809 -13.
  • •Turashvili G, McKinney S, Martin L, Gelmon KA, Watson P, Boyd N, Aparicio S. Columnar cell lesions, mammographic density and breast cancer risk. Breast Cancer Res Treat 2009; 115(3): 561 -71.
  • •Yerushalmi R and Gelmon KA.  Mucinous breast carcinoma: a large contemporary serise.  Commentary Breast Diseases; A year Book Quarterly 2009 (20) 167.
  • •Yerushalmi R, and Gelmon KA, Histologic associations and long terms cancer risk in columnar cell lesions of the breast. A retrospective cohort and nested case control study. Commentary Breast Disease: A year book quarterly 2009; 20 (2): 168-9.
  • •Yerushalmi R, Hayes M, Gelmon KA.  Rare Epithelial Breast Cancers.  Annals of Oncology, 2009; 20 (11): 1763-70.
  • •Yerushalmi R, Kramer MR, Rizel S, Sulkes A, Gelmon K, Granot T, Neiman V, Stemmer SM.  Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study.  Ann Oncol 2009; 20 (3): 437-40.
  • •Yerushalmi R. woods R, Kennecke H, Speers C, Knowling M, Gelmon K.  Patterns of relapse in breast cancer: changes over time. Breast Cancer Research and Treatment 2009; 120 (3): 753-759.
  • •Yerushalmi, R, Hayes M,  Gelmon, K, Chia S, Bajdik, C, Norris, B, Speers C, Hassell P, O’Reilly S, Allan S, Shenkier, T.  A Phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: Pathologic response, long term followup and correlation with biomarkers.   Clinical Breast Cancer 2009 Aug; Vol. 9 (3), pp. 166-72.
  • •Baselga Jose, Gelmon K, Verma S, Wardley AM, Conte PF, Miles DW, Bianchi GV, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L.  A Phase II trial of pertuzumab and trastuzumab in patients with HER2 positive metastatic breast cancer that had progressed during prior trastuzumab therapy.  Jour Clin Oncol 2010; 28 (7) : 1138-1144.
  • •Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Keikkia P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM,  Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival; a collaborative analysis of data for 10, 159 cases from 12 studies. PLos Med. 2010; 7(5): e1000279.
  • •Burnell M, Levine M, Chapman JW, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal HI, Albain K, Perez E, Rugo H, Pritchard KI, O’Brien P, Ding Z, Shepherd L.  A trial of CEF versus Dose Dense EC followed by Paclitaxel versus AC follwed by Paclitaxel in women with node positive or high risk node negative breast cancer; NCIC CTG- MA21.  J Clin Oncol 2010; 28 (1): 77 -82.
  • •Burstein H, Prestrud A, Seidenfeld J, Anderson H, Buchholz T, Davidson N, Gelmon K, Giordano S, Hudis C, Malin J, Mamounas EP, Rowden D, Solky A, Sowers MF, Stearns V, Somerfield M, Winer E, Griggs J.  American Society Of Clinical Oncology Clinical Practice Guidelines: 2009 update on adjuvant endocrine therapy for women with hormone positive breast cancer.  Jour Clin Oncol 2010; 28 (23); 3784-3796.
  • •Clemons M, Joy AA, Abdulnabi R, Kotliar M, Lynch J, Jordaan JP, Iscoe N, Gelmon K. Phase II double blind randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. Breast Cancer Res Treat 2010; 124(1): 177-86.
  • •Dawson SJ, Makretsov N, Blows F, Driver K, Proovenzano E, LeQuesne J, Baglietto L, Severi G, Giles G, McLean C Callagy G, Green A, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P. BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.  Br J Cancer 2010; 103(5): 668 -75.
  • •Dolan LB, Gelmon K, Courneya KS, Mackey JR, Segal RJ, Lane K, Reid D, McKenzie DC. Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy. Cancer Epidem Biomarkers Prev 2010; 19(11): 2826-32.
  • •Gelmon KA. The ongoing debate about nodes. Clin Breast Cancer 2010; 10 (4): 265-66.
  • •Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. Suppression of HER2/neu expression through ILK inhibition is regulated by a pathway involved TWIST and YB-1. Oncogene, 2010; 29(48): 6343-56.
  • •Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO, Gelmon K. The metastatic behaviour of breast cancer subtypes. J Clin Oncol 2010; 28 (20): 3271 – 3277.
  • •Korde LA, Zujewski JA, Kamin L, Giordano SH, Domchek SM, Anderson W, Barlett JMS, Gelmon KA, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. A Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations. Jour Clin Oncol 2010; 28 (12): 2114-22.
  • •Rayson D, Gelmon, K.  Accrual strategies for cancer genetic research: blurred boundaries. J Clin Oncol 2010; 28 (18); e 308.
  • •Voduc D, Cheang MCU, Nielsen TO, Tyldesley S, Gelmon K, Kennecke H.  Breast cancer subtypes and the risk of local and regional relapse.  JCO 2010: 1684-1691.
  • •Yerushalmi R, Gelmon K. Treatment beyond progression: is it moving from belief to evidence? Oncologist 2010 15 (8): 796-8.
  • •”Yerushalmi, R, Woods R, Ravidin P, Hayes M, Gelmon KA.  Ki-67 in breast cancer:
  • •review of the literature and update of the prognostic and predictive potential of Ki67.  Lancet Oncology 2010; 11:174-183.”
  • •Davidson A, Gelmon K. Do anthracyclines have a role in the adjuvant treatment of breast cancer? Future Oncology; 2011; 7(1): 37-55.
  • •Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepher LE. Evaluation of metformin in early breast cancer; A  modification of the traditional paradigm for clinical testing of anti cancer agents. Breast Cancer Treat 2011; 123: 215-20.
  • •Macfarlane RJ, Gelmon K. Lapatinib for breast cancer: a review of the current literature. Drug Safety Evaluation 2011; 10(1): 109-21.
  • •Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los G, Rejto PA, Aparicio SA. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Modern Pathology 2011; 24(1): 64-81.

Awards & Recognition